No connection

Search Results

Healthcare Score 75 Cautious concern

Discontinuing GLP-1 Diabetes Drugs Linked to Increased Risk of Heart Attack, Stroke and Death, Study Finds

Mar 18, 2026 18:06 UTC
NVO, LLY, ^VIX
Short term

A new study reveals that even brief interruptions in GLP-1 medication use significantly raise the risk of heart attack, stroke, and death among patients with Type 2 diabetes. The findings may influence patient adherence and investor sentiment in the biotech sector.

  • Discontinuing GLP-1 diabetes medications increases the risk of heart attack, stroke, and death.
  • Even short treatment gaps are associated with elevated cardiovascular risks.
  • Eli Lilly (LLY) and Novo Nordisk (NVO) are key companies with GLP-1 drug portfolios affected.
  • The findings may impact patient adherence and long-term drug demand.
  • Volatility index ^VIX may reflect shifting investor sentiment in the healthcare sector.

Patients with Type 2 diabetes who stop using GLP-1 medications—even temporarily—face a heightened risk of serious cardiovascular events and mortality, according to recent research. The study underscores the critical importance of continuous treatment for maintaining long-term health outcomes in this patient population. The findings carry significant implications for pharmaceutical companies with major GLP-1 drug portfolios, including Eli Lilly (LLY) and Novo Nordisk (NVO). As adherence becomes a growing concern, the data may prompt healthcare providers and payers to emphasize consistent use of these therapies. While the study does not specify exact risk percentages or duration thresholds for increased danger, it confirms that treatment gaps, regardless of length, are associated with adverse outcomes. This could impact market dynamics in the healthcare and biotech sectors, particularly around drug retention and long-term demand projections. The results may also influence investor behavior, with potential ripple effects on stock performance and sector sentiment, as reflected in volatility indicators such as the ^VIX. The study adds to the growing body of evidence supporting the cardiovascular benefits of GLP-1 therapies, reinforcing their clinical value beyond glucose control.

Sign up free to read the full analysis

Create a free account to unlock full AI-curated market articles, personalized alerts, and more.

Create Free Account Already have an account? Sign In
Share this article

Related Articles

Score 85

Gold Stabilizes Near $5,000/oz After Six-Day Drop Amid Fed Inflation Warnings

Mar 18, 22:33

Score 95 Bearish

Asian Stocks to Fall as Iran War Saps Sentiment: Markets Wrap

Mar 18, 22:31

Score 85

Powell Signals Will Remain in Role Amid Delayed Confirmation of Successor Warsh

Mar 18, 22:25

Score 75 Bearish

S&P 500 Nears Critical Technical Break, Analyst Warns of 10% Drop

Mar 18, 22:13

Stay Ahead of the Markets

Join thousands of traders using AI-powered market intelligence. Get personalized insights, real-time alerts, and advanced analysis tools.

Get Started Free View Plans
Features Intelligence Terminal AI Assistant Trading Challenge Analysis Market News Pricing
Start Trading with AI Already have an account? Sign In
Home
Terminal
AI
Markets
Profile